c7aea5a2-5772-4475-8ca6-326193eeb69e
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 79
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.580
- MYC_TARGETS_V1+0.510
- PROTEIN_SECRETION+0.470
- FATTY_ACID_METABOLISM+0.440
- MTORC1_SIGNALING+0.440
- ADIPOGENESIS+0.370
- E2F_TARGETS+0.370
- XENOBIOTIC_METABOLISM+0.330
- PEROXISOME+0.310
- MYC_TARGETS_V2+0.300
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.370
- HEDGEHOG_SIGNALING-0.360
- MITOTIC_SPINDLE-0.310
- PANCREAS_BETA_CELLS-0.310
- TNFA_SIGNALING_VIA_NFKB-0.310
- MYOGENESIS-0.270
- UV_RESPONSE_DN-0.240
- APICAL_JUNCTION-0.220
- KRAS_SIGNALING_DN-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 77984740-019e-482f-822a-25a74ec2cc32 | — | — | 0.905 |
| 2 | TCGA-37-4133-01A-01R-1100-07 | — | cohortSQ1 | 0.861 |
| 3 | SRR17866853 | — | — | 0.858 |
| 4 | 1a68a242-045b-4566-afd7-192df87b02d3 | — | — | 0.851 |
| 5 | 8824c0fd-764e-4525-952b-f25efa742772 | — | — | 0.851 |
| 6 | 930630ee-1c36-4567-aeff-042eef1654e6 | — | — | 0.841 |
| 7 | 94a92a4a-6c40-40c4-913d-0cdba8cb5892 | — | — | 0.839 |
| 8 | TCGA-A8-A09W-01A-11R-A00Z-07 | — | B | 0.834 |
| 9 | 054d5602-4089-4f34-a667-14c8edbb4167 | — | — | 0.828 |
| 10 | SRR6013495 | — | cohortA1 | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.580 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.470 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.440 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.440 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.370 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.330 | Inavolisib | — uncovered |
| PEROXISOME | 0.310 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.260 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.240 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.230 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.220 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |